false000175014900017501492022-06-242022-06-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2022

 

 

INHIBIKASE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

 

 

 

 

 

Delaware

(State or Other Jurisdiction

of Incorporation)

 

001-39676

(Commission

File Number)

 

26-3407249

(IRS Employer

Identification No.)

 

 

 

 

3350 Riverwood Parkway SE, Suite 1900

Atlanta, Georgia

 

30339

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (678) 392-3419

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 


 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 par value

 

IKT

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

The 2022 Annual Meeting of Stockholders (“Annual Meeting”) of Inhibikase Therapeutics, Inc. (the “Company”) was held on June 24, 2022. The following proposals were approved at the Annual Meeting by the votes indicated:

Proposal One: To elect two directors to the board of directors of the Company to serve as Class II directors, to serve until the Company’s 2025 annual meeting of stockholders or until in each case their respective successor is duly elected and qualified. The nominees for election were Roy Freeman, M.D and Paul Grint, M.D.

The following nominees were elected by the votes indicated to serve as Class II directors, to serve until the Company’s 2025 annual meeting of stockholders or until their respective successors are duly elected and qualified:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name

 

Total Votes
for Director

 

 

Total Votes
Withheld from
Director

 

 

Total Broker
Non-Votes

 

Roy Freeman, M.D.

 

 

11,443,604

 

 

 

574,448

 

 

 

4,467,473

 

Paul Grint, M.D.

 

 

11,530,376

 

 

 

487,676

 

 

 

4,467,473

 

Proposal Three: To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

 

 

 

 

 

 

 

 

Total Votes

 

For

 

 

16,397,389

 

Against

 

 

31,521

 

Abstain

 

 

56,614

 

Broker Non-Votes

 

 

0

 

 

-2-

 


The following proposal was not adopted at the Annual Meeting by the votes indicated because the requisite approval percentage was not met:

Proposal Two: To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000.

 

 

 

 

 

 

 

Total Votes

 

For

 

 

15,007,293

 

Against

 

 

1,428,440

 

Abstain

 

 

49,792

 

Broker Non-Votes

 

 

0

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

Date: June 29, 2022

 

 

 

INHIBIKASE THERAPEUTICS, INC.

 

 

 

 

 

 

 

 

By:

 

/S/ MILTON H. WERNER

 

 

 

 

 

 

Milton H. Werner, Ph.D.

 

 

 

 

 

 

President and Chief Executive Officer

 

-3-